The U.S. District Court for the Southern District of Florida issued a final judgment of $680,235.05 against Nutra Pharma Corporation in August 2024. This action concluded a long-running securities fraud case brought by the Securities and Exchange Commission (SEC) against the company. The total sum includes $520,940 in disgorgement, $59,295.05 in prejudgment interest, and a $100,000 civil penalty.
Nutra Pharma, a publicly traded entity on the OTC Markets, once promoted Nyloxin, a supposed pain-relief product. The company claimed the active ingredient was cobra venom. This product was primarily distributed through MyNyloxin, a multi-level marketing (MLM) operation. MyNyloxin ceased operations in January 2015. A subsequent attempt to restart under the name Lumaxa also failed to gain traction.
The SEC initiated its lawsuit against Nutra Pharma Corporation in late 2018. The agency alleged securities fraud and a scheme to manipulate the company's share price. The complaint specifically named CEO Erik Deitsch and consultant Sean McManus as key figures in the alleged misconduct. The SEC's complaint detailed how Nutra Pharma and its executives made materially false and misleading statements to investors, aiming to inflate the company's stock value.
Both Deitsch and McManus reached settlements with the SEC in May 2024. Deitsch agreed to pay $44,046 in disgorgement, $5,013 in prejudgment interest, and a $30,000 civil penalty. McManus, for his part, paid $5,500 in disgorgement, $625 in prejudgment interest, and a $5,500 civil penalty. These individual settlements preceded the final judgment against the corporation itself, bringing an end to the litigation for the named defendants.
Beyond the securities fraud allegations, Nutra Pharma and Erik Deitsch faced scrutiny from health regulators. In 2019, the Food and Drug Administration (FDA) issued a warning letter regarding MyNyloxin. The FDA cited the company for marketing its cobra venom product as a treatment for conditions such as drug addiction, chronic arthritis, Parkinson's disease, and cancer. The agency determined that none of these claims were substantiated by scientific evidence. Consequently, the FDA classified MyNyloxin's entire product line as "unapproved new drugs" under federal law. Marketing unapproved drugs makes a product misbranded and adulterated, posing a risk to public health.
The FDA's intervention underscored the deceptive nature of the product claims, which often coincided with promotional efforts that allegedly manipulated Nutra Pharma's stock. Investors who purchased Nutra Pharma shares on the open market, particularly those trading on over-the-counter exchanges, were exposed to potential losses as a result of the alleged misrepresentations. The SEC's action aimed to recover ill-gotten gains and impose penalties for the harm caused to the market and investors.
Erik Deitsch has since moved to a new venture. He currently serves as the Chief Scientific Officer for Avini Health. This company also operates as a multi-level marketing scheme, marketing health and wellness supplements through a recruitment-based autoship model.
Victims of securities fraud can find information and resources regarding investor protection at the SEC's Investor.gov website.